Tremor
146 results
1 - 100
Pregabalin for essential tremor- Alprazolam for essential tremor
- Zonisamide for essential tremor
- Topiramate for essential tremor
- Beta‐blocker therapy for tremor in Parkinson's disease
- Treatment for ataxia in multiple sclerosis
- Anticholinergics for symptomatic management of Parkinson´s disease
- Chlorpromazine versus placebo for schizophrenia
- Risperidone (depot) for schizophrenia
- Tiagabine add‐on therapy for drug‐resistant focal epilepsy
- Bromocriptine versus levodopa in early Parkinson's disease
- Cholinesterase inhibitors for Parkinson's disease dementia
- Bromocriptine/levodopa combined versus levodopa alone for early Parkinson's disease
- Amantadine in Parkinson's disease
- Anticholinergic bronchodilators versus beta2‐sympathomimetic agents for acute exacerbations of chronic obstructive pulmonary disease
- Pimozide for schizophrenia or related psychoses: Cochrane systematic review
- Pharmacotherapy for weight loss in adults with type 2 diabetes mellitus
- Magnesium for alcohol withdrawal: Cochrane systematic review
- Olanzapine for schizophrenia: Cochrane systematic review
- Antipsychotic medication for elderly people with schizophrenia
- Anticholinergic therapy for acute asthma in children: Cochrane systematic review
- Inhaled bronchodilators for the prevention and treatment of chronic lung disease in preterm infants
- Beta2-adrenoceptor agonists for dysmenorrhoea: Cochrane systematic review
- Mirtazapine versus other antidepressive agents for depression: Cochrane systematic review
- Oral xanthines as maintenance treatment for asthma in children
- Perphenazine for schizophrenia
- Antiepileptic drugs for preventing seizures in people with brain tumors
- Prophylactic oral betamimetics for preventing preterm labour in singleton pregnancies
- Aripiprazole for autism spectrum disorders (ASD)
- Comparison of speech and language therapy techniques for speech problems in Parkinson's disease
- Addition of long-acting beta2-agonists to inhaled steroids versus higher dose inhaled steroids in adults and children with persistent asthma: Cochrane systematic review
- Combined inhaled anticholinergics and short‐acting beta2‐agonists for initial treatment of acute asthma in children
- Antiepileptic drugs for the primary and secondary prevention of seizures after subarachnoid haemorrhage
- Inhaled beta2‐agonists for non‐specific chronic cough in children
- Beta2‐agonists for acute cough or a clinical diagnosis of acute bronchitis
- Perazine for schizophrenia
- Pericyazine for schizophrenia
- Addition of intravenous beta 2 -agonists to inhaled beta 2 -agonists for acute asthma: Cochrane systematic review
- Dance therapy for schizophrenia
- Fluphenazine versus low‐potency first‐generation antipsychotic drugs for schizophrenia
- Dopamine agents for hepatic encephalopathy
- Chlorpromazine versus atypical antipsychotic drugs for schizophrenia
- Methadone at tapered doses for the management of opioid withdrawal
- Quetiapine versus other atypical antipsychotics for schizophrenia
- Lithium for acute mania
- Fluphenazine decanoate (depot) and enanthate for schizophrenia: Cochrane systematic review
- Trifluoperazine versus low‐potency first‐generation antipsychotic drugs for schizophrenia
- Efficacy and safety of pharmacological interventions for the treatment of the Alcohol Withdrawal Syndrome
- Chlorpromazine versus metiapine for schizophrenia
- Haloperidol versus first‐generation antipsychotics for the treatment of schizophrenia and other psychotic disorders
- Methylxanthines for exacerbations of chronic obstructive pulmonary disease
- Chlorpromazine dose for people with schizophrenia
- Intermittent drug techniques for schizophrenia
- Speech and language therapy versus placebo or no intervention for speech problems in Parkinson's disease
- Quetiapine versus typical antipsychotic medications for schizophrenia
- Perphenazine versus low‐potency first‐generation antipsychotic drugs for schizophrenia
- Haloperidol alone or in combination for acute mania
- Tacrolimus versus cyclosporin as primary immunosuppression for kidney transplant recipients
- Clozapine combined with different antipsychotic drugs for treatment‐resistant schizophrenia
- Gamma‐hydroxybutyrate (GHB) for treatment of alcohol withdrawal and prevention of relapses
- Haloperidol versus placebo for schizophrenia
- Fluphenazine (oral) versus placebo for schizophrenia
- Intravenous aminophylline for acute severe asthma in children over two years receiving inhaled bronchodilators
- Sertindole for schizophrenia
- Holding chambers (spacers) versus nebulisers for beta‐agonist treatment of acute asthma
- Flupenthixol versus low-potency first-generation antipsychotic drugs for schizophrenia: Cochrane systematic review
- Tricyclic drugs for depression in children and adolescents
- Immunotherapy for IgM anti‐myelin‐associated glycoprotein paraprotein‐associated peripheral neuropathies
- Non‐absorbable disaccharides versus placebo/no intervention and lactulose versus lactitol for the prevention and treatment of hepatic encephalopathy in people with cirrhosis
- Atypical antipsychotics for autism spectrum disorder: a network meta‐analysis
- Valproic acid, valproate and divalproex in the maintenance treatment of bipolar disorder